The term `cirrhosis` is used for two centuries to define the end-stage of chronic liver diseases with different etiologies. Clinical manifestations of cirrhosis are related to portal hypertension, hepatic dysfunction progressing to liver failure and development of hepatocellular carcinoma, conditions with unfavorable prognosis. However, recent advances in the diagnosis and treatment of chronic liver diseases have changed the natural history of cirrhosis significantly. According to current concept, liver cirrhosis is heterogeneous, multi-stage condition with variable prognosis. Cirrhosis is considered as a dynamic, biphasic process, based on numerous clinical reports indicating the reversal of advanced fibrosis and cirrhosis after cessation of perpetual injury. This review was focused on current pathology and clinical staging of cirrhosis. The potential mechanism and proves of concept for reversibility of cirrhosis were also discussed.
Schuppan D, Afdhal NH, Israel B. Liver cirrhosis. Lancet. 2008;371:838–51.
De Franchis R. Expanding consensus in portal hypertension. J Hepatol. 2016; 30;63(3):743–52.
Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol.2009; 104(5):1147–58.
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol. 2006; 44:217–31.
Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014; 60(1):197–209.
Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146(6):1513–24.
Friedman SL. Replacing a crystal ball with a calculator in predicting liver disease outcomes. J Hepatol. 2014;60(5):905–6.
Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology. 2010; 51: 445–9.
Arvaniti V, D’Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining Prognosis. Gastroenterology. 2010;139(4):1246–56.
Hytiroglou P, Snover DC, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, et al. Beyond “cirrhosis.” American Journal of Clinical Pathology. 2012; 137 (1): 5–9.
Kim MY, Cho MY, Baik SK, Park HJ, Jeon HK, Im CK, et al. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol. 2011;55(5):1004-9.
Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis - A histological classification of the severity of cirrhosis. J Hepatol. 2006;44:111-7.
Tsochatzis E, Bruno S, Isgro G, Hall A, Theocharidou E, Manousou P, et al. Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. J Hepatol. 2014;60(5):948-54.
Kumar M, Sakhuja P, Kumar a., Manglik N, Choudhury a., Hissar S, et al. Histological subclassification of cirrhosis based on histological- haemodynamic correlation. Aliment Pharmacol Ther. 2008;27(9):771-9.
Sethasine S, Jain D, Groszmann RJ, Garcia-Tsao G. Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology. 2012;55(4):1146-53.
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64.
Pellicoro A, Ramachandran P, Iredale JP, Fallowfield J. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181-94.
Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int. 2015; 35(1):30-6.
Calvaruso V, Craxà A. Regression of fibrosis after HBV antiviral therapy: Is cirrhosis reversible? Liver International. 2014; 34 (Suppl.1). 85-90.
Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000; 124(11):1599-607.
D`Ambrosio R, Aghemo A. Treatment of patients with HCV related cirrhosis: Many rewards with very few risks. Hepat Mon. 2012;12:102-9.
Aghemo A, Lampertico P, Colombo M. Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. J Hepatol. 2012;57(6):1326-35.
Email this article (Login required) 
